Sign up to access all valuation multiples
Ebos is the second-largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government’s Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
1922
5.2K+
LTM Revenue $8.9B
LTM EBITDA $423M
$4.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ebos Group has a last 12-month revenue (LTM) of $8.9B and a last 12-month EBITDA of $423M.
In the most recent fiscal year, Ebos Group achieved revenue of $7.7B and an EBITDA of $338M.
Ebos Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ebos Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.9B | XXX | $7.7B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA | $423M | XXX | $338M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| EBIT | $331M | XXX | $265M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $186M | XXX | $135M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $576M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Ebos Group's stock price is NZD 32 (or $18).
Ebos Group has current market cap of NZD 6.5B (or $3.8B), and EV of NZD 8.0B (or $4.7B).
See Ebos Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7B | $3.8B | XXX | XXX | XXX | XXX | $0.85 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Ebos Group has market cap of $3.8B and EV of $4.7B.
Ebos Group's trades at 0.6x EV/Revenue multiple, and 13.0x EV/EBITDA.
Equity research analysts estimate Ebos Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ebos Group has a P/E ratio of 22.3x.
See valuation multiples for Ebos Group and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.8B | XXX | $3.8B | XXX | XXX | XXX |
| EV (current) | $4.7B | XXX | $4.7B | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 12.1x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBIT | 15.5x | XXX | 16.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 22.3x | XXX | 24.4x | XXX | XXX | XXX |
| EV/FCF | 23.2x | XXX | 23.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEbos Group's last 12 month revenue growth is 7%
Ebos Group's revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $0.1M for the same period.
Ebos Group's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ebos Group's rule of X is 22% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ebos Group and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 11% | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Sigma Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Profarma Distribuidora | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ebos Group acquired XXX companies to date.
Last acquisition by Ebos Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Ebos Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Ebos Group founded? | Ebos Group was founded in 1922. |
| Where is Ebos Group headquartered? | Ebos Group is headquartered in New Zealand. |
| How many employees does Ebos Group have? | As of today, Ebos Group has 5.2K+ employees. |
| Is Ebos Group publicy listed? | Yes, Ebos Group is a public company listed on NZE. |
| What is the stock symbol of Ebos Group? | Ebos Group trades under EBO ticker. |
| When did Ebos Group go public? | Ebos Group went public in 1960. |
| Who are competitors of Ebos Group? | Similar companies to Ebos Group include e.g. Sigma Healthcare, MedPlus India, SC Ropharma, Profarma Distribuidora. |
| What is the current market cap of Ebos Group? | Ebos Group's current market cap is $3.8B |
| What is the current revenue of Ebos Group? | Ebos Group's last 12 months revenue is $8.9B. |
| What is the current revenue growth of Ebos Group? | Ebos Group revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Ebos Group? | Current revenue multiple of Ebos Group is 0.6x. |
| Is Ebos Group profitable? | Yes, Ebos Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ebos Group? | Ebos Group's last 12 months EBITDA is $423M. |
| What is Ebos Group's EBITDA margin? | Ebos Group's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Ebos Group? | Current EBITDA multiple of Ebos Group is 12.1x. |
| What is the current FCF of Ebos Group? | Ebos Group's last 12 months FCF is $222M. |
| What is Ebos Group's FCF margin? | Ebos Group's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Ebos Group? | Current FCF multiple of Ebos Group is 23.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
